Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Day Trading Penny Stocks to Buy.

On April 28, 2026, Canaccord lowered its price target on Compass Therapeutics, Inc. (NASDAQ:CMPX) to $7 from $13 and maintained a Buy rating. The firm said Tovecimig+paclitaxel showed improved progression-free survival versus paclitaxel monotherapy, but noted that 54% crossover complicated the interpretation of any overall survival benefit in the ITT population. Canaccord added that while the active arm showed numerically better overall survival among patients who did not crossover, it does not expect this to be enough for full FDA approval.

In a similar move, Stifel reduced its price target on Compass Therapeutics, Inc. (NASDAQ:CMPX) to $6 from $12 while keeping a Buy rating. Stifel said COMPANION-002 secondary endpoint data support the efficacy of tovecimig, shifting the discussion toward how the FDA may interpret the results. The firm noted that several questions are likely to shape the near-term narrative but reiterated its Buy rating, pointing to tovecimig optionality and an earlier-stage pipeline with upcoming catalysts.

Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)

Meanwhile, Jefferies said the 63% selloff in Compass Therapeutics appears “an over-reaction,” citing the company’s data and the biliary tract cancer opportunity, while adding that the trial’s crossover design “confounds the ITT readout” even as it maintained a Buy rating and a $9 price target.

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics for the treatment of various human diseases in the United States.

While we acknowledge the risk and potential of CMPX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CMPX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.